Galimedix Therapeutics Initiates Phase 1 Trial of Oral GAL-101 for Amyloid Beta Modulation
• Galimedix Therapeutics has begun a Phase 1 clinical trial for oral GAL-101, an amyloid beta (Aβ) aggregation modulator, to assess its safety and tolerability.
• The trial will evaluate single and multiple ascending doses of GAL-101, an orally administered therapy, focusing on pharmacokinetics.
• The merged entity of Tenpoint Therapeutics and Visus Therapeutics focuses on addressing ocular conditions related to aging, including presbyopia and cataracts.
Phase 1/2 Trial Investigates 225Ac-J591 and 177Lu-PSMA-I&T Combination in Metastatic Castration-Resistant Prostate Cancer
• A phase 1/2 trial (NCT04886986) is evaluating the safety and efficacy of combining 225Ac-J591 with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC).
• The phase 1 dose-escalation study involves administering a fixed dose of 177Lu-PSMA-I&T plus escalating doses of 225Ac-J591 to mCRPC patients.
• Early results from the phase 1 trial suggest that 225Ac-J591 is tolerable, with no dose-limiting toxicities observed in the initial cohorts, though one patient experienced grade 3 thrombocytopenia.
• The trial is ongoing, and further follow-up is needed to fully assess the safety and efficacy of this combination therapy in mCRPC.
© Copyright 2025. All Rights Reserved by MedPath